Does the cytokine adsorber CytoSorb
Adsorption
Critically ill patients
CytoSorb®
Pharmacokinetics
Sepsis
Vancomycin
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
01
09
2021
accepted:
06
05
2022
entrez:
22
5
2022
pubmed:
23
5
2022
medline:
23
5
2022
Statut:
epublish
Résumé
Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb 20 CytoSorb We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb
Sections du résumé
BACKGROUND
BACKGROUND
Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb
METHODS
METHODS
Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb
RESULTS
RESULTS
20 CytoSorb
CONCLUSION
CONCLUSIONS
We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb
Identifiants
pubmed: 35599248
doi: 10.1186/s13613-022-01017-5
pii: 10.1186/s13613-022-01017-5
pmc: PMC9124739
doi:
Banques de données
ClinicalTrials.gov
['NCT03985605']
Types de publication
Journal Article
Langues
eng
Pagination
44Subventions
Organisme : Medizinischen Fakultät, Ludwig-Maximilians-Universität München
ID : FöFoLe No. 002
Informations de copyright
© 2022. The Author(s).
Références
Gotts JE, Matthay MA. Sepsis pathophysiology and clinical management. British Med J. 2016. https://doi.org/10.1136/bmj.i1585 .
doi: 10.1136/bmj.i1585
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.
doi: 10.1001/jama.2016.0287
Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75–87.
doi: 10.1016/S0140-6736(18)30696-2
Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain MLNG, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care. 2019;9:56.
doi: 10.1186/s13613-019-0530-y
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.
doi: 10.1097/01.CCM.0000217961.75225.E9
Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:7.
doi: 10.1097/CCM.0000000000000330
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35–9.
doi: 10.1086/491712
Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J. Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother. 2016;60:2601–9.
doi: 10.1128/AAC.03147-14
German S2k guideline parenteral antibiotics 2020 https://www.awmf.org/uploads/tx_szleitlinien/S82-006l_S2k_Parenterale_Antibiotika_2018-1.pdf .
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by the american society of health-system pharmacists, the infectious diseases society of america, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020;77:835–64.
doi: 10.1093/ajhp/zxaa036
Poli EC, Rimmelé T, Schneider AG. Hemoadsorption with CytoSorb®. Intensive Care Med. 2019;45:236–9.
doi: 10.1007/s00134-018-5464-6
CytoSorbents Europe GmbH https://cytosorb-therapy.com .
Stenken JA, Poschenrieder AJ. Bioanalytical chemistry of cytokines—a review. Anal Chim Acta. 2015;853:95–115.
doi: 10.1016/j.aca.2014.10.009
Mendes V, Colombier S, Verdy F, Bechtold X, Schlaepfer P, Scala E, et al. Cytosorb® hemoadsorption of apixaban during emergent cardio pulmonary bypass: a case report. Perfusion. 2020. https://doi.org/10.1177/0267659120967827 .
doi: 10.1177/0267659120967827
pubmed: 33106093
Lang CN, Sommer MJ, Neukamm MA, Staudacher DL, Supady A, Bode C, et al. Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study. Intensive Care Med Exp. 2020;8:21.
doi: 10.1186/s40635-020-00313-3
Schroeder I, Zoller M, Angstwurm M, Kur F, Frey L. Venlafaxine intoxication with development of takotsubo cardiomyopathy: successful use of extracorporeal life support, intravenous lipid emulsion and cytosorb®. Int J Artif Organs. SAGE Pub Ltd STM. 2017;40:358–60.
König C, Röhr AC, Frey OR, Brinkmann A, Roberts JA, Wichmann D, et al. In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Org. 2019;42:57–64.
doi: 10.1177/0391398818812601
Reiter K, BordoniDall’Olio VG, Ricatti MG, Soli M, Ruperti S, et al. In vitro removal of therapeutic drugs with a novel adsorbent system. Blood Purif. 2002;20:380–8.
doi: 10.1159/000063108
Dimski T, Brandenburger T, MacKenzie C, Kindgen-Milles D. Elimination of glycopeptide antibiotics by cytokine hemoadsorption in patients with septic shock: a study of three cases. Int J Artif Organs. 2020;43:753–7.
doi: 10.1177/0391398820917151
Scandroglio AM, Pieri M, Nardelli P, Fominskiy E, Calabrò MG, Melisurgo G, et al. Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Artif Organs. 2021. https://doi.org/10.1111/aor.13952 .
doi: 10.1111/aor.13952
pubmed: 33686696
Ankawi G, Xie Y, Yang B, Xie Y, Xie P, Ronco C. What have we learned about the use of cytosorb adsorption columns? Blood Purif. 2019;48:196–202.
doi: 10.1159/000500013
Liebchen U, Paal M, Scharf C, Schroeder I, Grabein B, Zander J, et al. The ONTAI study—a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. J Crit Care. 2020;60:260–6.
doi: 10.1016/j.jcrc.2020.08.027
Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–53.
doi: 10.1007/s00134-020-06050-1
Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs in Biomed. 2005;79:241–57.
doi: 10.1016/j.cmpb.2005.04.005
Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9.
doi: 10.1016/j.cmpb.2010.04.018
Schneider AG, André P, Scheier J, Schmidt M, Ziervogel H, Buclin T, et al. Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Sci Rep. 2021;11:10493.
doi: 10.1038/s41598-021-89965-z
European Medicines Agency 2018 Investigation of drug interactions. https://www.ema.europa.eu/en/investigation-drug-interactions .
Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction failure in intensive care units: results of a multicentre, prospective study Working group on “sepsis-related problems” of the European society of intensive care medicine. Crit Care Med. 1998. https://doi.org/10.1097/00003246-199811000-00016 .
doi: 10.1097/00003246-199811000-00016
pubmed: 9875924
Jamal J-A, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med. 2014;42:1640–50.
doi: 10.1097/CCM.0000000000000317
Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy a monte carlo simulation study. J Intensive Care. 2018. https://doi.org/10.1186/s40560-018-0330-8 .
doi: 10.1186/s40560-018-0330-8
pubmed: 30221005
pmcid: 6134777
Broeker A, Vossen MG, Thalhammer F, Wallis SC, Lipman J, Roberts JA, et al. An integrated dialysis pharmacometric (idp) model to evaluate the pharmacokinetics in patients undergoing renal replacement therapy. Pharm Res. 2020;37:96.
doi: 10.1007/s11095-020-02832-w
Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolff F, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother. 2013;68:2859–65.
doi: 10.1093/jac/dkt261
van de Vijsel LM, Walker SAN, Walker SE, Yamashita S, Simor A, Hladunewich M. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Can J Hosp Pharm. 2010;63:196–206.
pubmed: 22478979
pmcid: 2901779
Li Q, Liang F, Sang L, Li P, Lv B, Tan L, et al. Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution. Eur J Clin Pharmacol. 2020;76:211–7.
doi: 10.1007/s00228-019-02755-5
Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, et al. Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol. 2020. https://doi.org/10.3389/fphar.2020.00786/full .
doi: 10.3389/fphar.2020.00786/full
pubmed: 33841131
pmcid: 7801264
Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Infect Chemother. 2013;19:365–80.
doi: 10.1007/s10156-013-0599-4
Buyle FM, Decruyenaere J, Waele J, Tulkens PM, Audenrode T, Depuydt P, et al. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol Infect Dis. 2013;32:763–8.
doi: 10.1007/s10096-012-1803-7
Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother. 2015;70:2671–7.
doi: 10.1093/jac/dkv165